Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Quantitative neuroiMaging In early Neurodegenerative Disease

Objetivo

Neurodegenerative diseases, including Alzheimer’s disease (AD), pose a major global health and economic challenge, with over 10 million new cases annually and costs exceeding $1.3 trillion. As the first AD-modifying therapies emerge, their effectiveness depends on identifying the right patients at the appropriate stage. However, current diagnostic and clinical trial-support tools, such as PET scans and lumbar punctures, are costly, poorly scalable and have safety risks. This impairs patient stratification and trial efficiency, and delays diagnosis until significant neuronal loss has occurred, limiting treatment impact.

We are developing a quantitative toolkit to enable early detection of AD-related brain changes, before irreversible clinical symptoms develop, allowing timely interventions that prevent disease progression. Our platform transforms routine, widely accessible Magnetic Resonance Imaging (MRI) scans into personalised, population-referenced markers of brain health, building on over a decade of research in advanced brain MRI analytics. Using AI-driven normative models, our approach supports better patient stratification, including selection of individuals likely to respond to therapy, thus improving clinical trial outcomes, and enable early diagnosis.

Within this proof-of-concept, we will: i) consolidate MRI-derived markers of early AD, building upon our pilot evidence, ii) benchmark them against PET and evaluate their predictive power for progressive AD phenotypes, iii) independently validate their performance through industry & clinical partners, iv) devise a commercialisation plan through planned market research. Utilising existing industry links, we will initially focus on enhancing patient selection for AD clinical trials, building the evidence base for regulatory approval and clinical translation. Ultimately, our toolset will be productised to allow emerging clinical care pathways to be optimised, improving patient outcomes and healthcare economics.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

THE UNIVERSITY OF NOTTINGHAM
Aportación neta de la UEn
€ 150 000,00
Dirección
University Park
NG7 2RD Nottingham
Reino Unido
Región
East Midlands (England) Derbyshire and Nottinghamshire Nottingham
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Beneficiarios (1)